Companies Investors People

Drop to look up

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

Get in Touch

Contact
Request a Demo
Request Data Updates
Add a Company

Research

Companies
Investors
People

aVenture

Download App
Pricing
Alternatives

For iPhone and iPad

Resources

Documentation
Use Cases
CLI
MCP
Sitemap

aVenture is an AI-native agentic deep research tool for researching and finding companies and people, and is a high-quality alternative to AlphaSense, CB Insights, Crunchbase, Dealroom, Harmonic, Owler, Perplexity Finance, PitchBook, Preqin, PrivCo, Synaptic, and Tracxn.

Member

Backed by

Ask AI about aVenture

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Terms of service

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

DNA Script

DNA Script

DNA Script makes SYNTAX, the benchtop enzymatic DNA printer that lets research labs synthesize oligos in-house overnight.

: Company
: 2014
: Le Kremlin-Bicêtre, FRFrance

DNA Script develops enzymatic DNA synthesis technology, built on its own work in enzyme engineering, surface and nucleotide chemistries, and instrumentation. Its business is the SYNTAX benchtop DNA synthesis platform and the SYNTAX reagent and run kits that feed it, which let labs produce high-quality ssDNA oligos overnight, in-house.

The SYNTAX platform performs enzymatic synthesis on a benchtop instrument in the customer's own lab, an alternative to ordering oligos from commercial suppliers, and produces oligos of equivalent or superior quality in error rate and run-to-run variability. DNA Script names its target customers as dsDNA providers, CROs, core facilities, and biotech, pharma, and governmental agencies.

Similar Companies

Biosplice Therapeutics

Bristol Myers Squibb

Vertex Pharmaceuticals

Pfizer

Novo Nordisk

Gilead Sciences

Amgen

AstraZeneca

Novartis

Merck

Roche Holding

AbbVie

Johnson & Johnson

Eli Lilly and Company

ZSPepLib

Immunai

EQT

T Rowe Price

Ansa Biotechnologies

ansabio.com

Molecular Assemblies

Kilobaser

kilobaser.com

Switchback Systems

switchbacksys.com

Quick Facts

Who are DNA Script's competitors?

Companies similar to DNA Script include Biosplice Therapeutics, Bristol Myers Squibb, Vertex Pharmaceuticals and Pfizer.

When was DNA Script founded?

DNA Script was founded in 2014.

Where is DNA Script's headquarters located?

DNA Script's headquarters is located in Le Kremlin-Bicêtre, FR.

How much disclosed funding has DNA Script raised?

As of the latest available date, DNA Script has disclosed funding of $470M (USD). Undisclosed round amounts are excluded.

Classification

Industry: Biopharmaceuticals
Biotech
Life Sciences Tools
Ownership: Venture-backed
Technology: Enzymatic DNA Synthesis
Geographic Exposure: Europe

Model: Product Sales
Revenue: Product Sales
Customer: B2B

Tags: Synthetic Biology

Also Known As: DNA Script SAS

Headquarters: 67 avenue de Fontainebleau
Le Kremlin-Bicêtre, 94270
FR